Related Experiment Videos
Therapeutic effects of Toxoplasma lysate antigen on 20-methylcholanthrene-induced BALB/c mouse tumors
1Department of Veterinary Clinical Radiology, Obihiro University, Hokkaido, Japan.
Abstract:
Therapeutic effects of Toxoplasma lysate antigen (TLA) were studied in mice bearing the tumor in the second passage of 20-methylcholanthrene (MC)-induced tumor cells. Intramuscular administration of TLA 7 days after the tumor-cell inoculation caused apparent inhibition of the tumor growth on day 14. The second treatment facilitated the therapeutic effects. Intravenous transfer of spleen cells prepared from TLA-sensitized mice into tumor-bearing mice also represented the growth inhibitory effects. Prominent effects were seen when the transferred cells were prepared 5 days after sensitization of donor animals. The inhibitory effects were absent in the groups transferred only the adherent cells or the non-adherent cells prepared from sensitized mice. The strongest inhibitory effect was observed in the group to which both adherent and non-adherent spleen cells were transferred simultaneously from sensitized mice. In in vitro experiments, spleen cells obtained from sensitized mice showed cytolytic effect on P-815 or YAC-1 cells after the secondary stimulation in vitro with TLA. Large non-adherent cells containing densely packed granules were induced when cultured with the adherent cells obtained from sensitized mice. These results revealed that TLA can inhibit the growth of the chemically-induced transplantable tumors by activation of adherent and non-adherent spleen cells.
Insights
Toxoplasma lysate antigen (TLA) effectively inhibited chemically-induced tumor growth in mice. This immunotherapy involved activating specific spleen cell populations, highlighting TLA
Area of Science:
- Immunology
- Cancer Research
- Parasitology
Background:
- Investigating novel immunotherapies for chemically-induced transplantable tumors.
- Exploring the potential of Toxoplasma lysate antigen (TLA) in cancer treatment.
- Understanding the role of spleen cells in anti-tumor responses.
Purpose of the Study:
- To evaluate the therapeutic efficacy of TLA against 20-methylcholanthrene (MC)-induced tumors in mice.
- To determine the contribution of spleen cell subsets in TLA-mediated tumor inhibition.
- To elucidate the in vitro mechanisms of TLA-induced anti-tumor activity.
Main Methods:
- Tumor induction in mice using 20-methylcholanthrene (MC)-induced tumor cells.
- Intramuscular administration of TLA and assessment of tumor growth inhibition.
- Adoptive transfer of spleen cells from TLA-sensitized mice into tumor-bearing recipients.
- In vitro assessment of spleen cell cytotoxicity against tumor cell lines (P-815, YAC-1) post-TLA stimulation.
- Separation and transfer of adherent and non-adherent spleen cell populations.
Main Results:
- TLA administration significantly inhibited tumor growth, with enhanced effects after a second treatment.
- Adoptive transfer of spleen cells from TLA-sensitized mice conferred significant tumor growth inhibition.
- Optimal therapeutic effects were achieved by transferring both adherent and non-adherent spleen cells simultaneously.
- In vitro studies demonstrated TLA-induced cytolytic activity of spleen cells against tumor targets.
- Culture of sensitized spleen cells with adherent cells induced large, granular non-adherent cells.
Conclusions:
- TLA demonstrates significant therapeutic potential against chemically-induced transplantable tumors.
- The anti-tumor effects of TLA are mediated through the activation of both adherent and non-adherent spleen cell populations.
- TLA-based immunotherapy warrants further investigation for cancer treatment applications.